Clinical Course and Prediction of Survival in Idiopathic Pulmonary Fibrosis
The DOI matches its Crossref record; 142 of the 142 references it cites were found in a registry or an index.
Abstract
Idiopathic pulmonary fibrosis (IPF) is a progressive, life-threatening, interstitial lung disease of unknown etiology. The median survival of patients with IPF is only 2 to 3 years, yet some patients live much longer. Respiratory failure resulting from disease progression is the most frequent cause of death. To date we have limited information as to predictors of mortality in patients with IPF, and research in this area has failed to yield prediction models that can be reliably used in clinical practice to predict individual risk of mortality. The goal of this concise clinical review is to examine and summarize the current data on the clinical course, individual predictors of survival, and proposed clinical prediction models in IPF. Finally, we will discuss challenges and future directions related to predicting survival in IPF.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.2.ats01 · Cited by 4,196
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Self-citationClinical Prediction Rules: Applications and Methodological Standards
Wasson, J. H., Sox, H. C., Neff, R. K., & Goldman, L. (1985) · New England Journal of Medicine · doi:10.1056/nejm198509263131306 · Cited by 1,357
Incidence and Prevalence of Idiopathic Pulmonary Fibrosis
Raghu, G., Weycker, D., Edelsberg, J., Bradford, W. Z., & Oster, G. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200602-163oc · Cited by 1,310 · cited 1×
“Older age is a clinical feature of IPF with a median age of 66 years at the time of diagnosis (1, 47).”
BackgroundAcute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationPrognostic Significance of Histopathologic Subsets in Idiopathic Pulmonary Fibrosis
BJORAKER, J. A., RYU, J. H., EDWIN, M. K., MYERS, J. L., TAZELAAR, H. D., SCHROEDER, D. R., & OFFORD, K. P. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.1.9704130 · Cited by 1,039 · cited 1×
“UIP is the histopathologic pattern that identifies IPF, and it carries the worst prognosis among the idiopathic interstitial pneumonias (2, 6, 8).”
BackgroundCombined pulmonary fibrosis and emphysema: a distinct underrecognised entity
Cottin, V., Nunes, H., Brillet, P.-Y., Delaval, P., Devouassoux, G., Tillie-Leblond, I., Israel-Biet, D., Court-Fortune, I., Valeyre, D., & Cordier, J.-F. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00021005 · Cited by 1,004 · cited 1×
“Emphysema affects the baseline pulmonary function tests by increasing lung volumes and decreasing DLCO and FEV1/FVC, as well as altering the change of these values over time, and therefore altering or masking the assessment of disease severity at baseline and progression over time (72, 73).”
BackgroundDouble-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-571oc · Cited by 954 · cited 1×
“trials: 1Pirfenidone (27), 2Imatinib (29), 3Interferon g-1b”
Pirfenidone in idiopathic pulmonary fibrosis
Taniguchi, H., Ebina, M., Kondoh, Y., Ogura, T., Azuma, A., Suga, M., Taguchi, Y., Takahashi, H., Nakata, K., Sato, A., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00005209 · Cited by 946 · cited 1×
“(IFNg) (25), 4Pirfenidone (30), 5Etanercept (26), 6Bosentan (24), 7N-Acetylcysteine (NAC) (28).”
Prevalence and Outcomes of Pulmonary Arterial Hypertension in Advanced Idiopathic Pulmonary Fibrosis
Lettieri, C. J., Nathan, S. D., Barnett, S. D., Ahmad, S., & Shorr, A. F. (2006) · Chest · doi:10.1378/chest.129.3.746 · Cited by 879 · cited 2×
“Other clinical parameters may be useful in selecting patients with higher pretest probability for having pulmonary hypertension in IPF, including reduced DLCO, use of supplemental oxygen, and poor performance on 6MWT (58).”
BackgroundEditorial: Cerebral Palsy—the International Consensus Statement
Clements, R. V., & Simanowitz, A. (2000) · Clinical Risk · doi:10.1177/135626220000600401 · Cited by 856
Predicting Survival in Idiopathic Pulmonary Fibrosis
KING, T. E., TOOZE, J. A., SCHWARZ, M. I., BROWN, K. R., & CHERNIACK, R. M. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.7.2003140 · Cited by 853 · cited 8×
“The CRP score is a clinical prediction model that has been developed in IPF (22).”
BackgroundMethodResultInfluentialSelf-citationinternational consensus statement
Clements, R. V., & Simanowitz, A. (2000) · Cited by 852
Pirfenidone in idiopathic pulmonary fibrosis: Figure 1–
Swigris, J., & Fairclough, D. (2010) · European Respiratory Journal · doi:10.1183/09031936.00071710 · Cited by 799
Laupacis, A. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540300056034 · Cited by 793
Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis.
Baumgartner, K. B., Samet, J. M., Stidley, C. A., Colby, T. V., & Waldron, J. A. (1997) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.155.1.9001319 · Cited by 767
Changes in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764 · cited 4×
“In general, factors that are associated with shortened survival time include: older age, smoking history, lower body mass index (BMI), more severe physiologic impairment, greater radiologic extent of disease, and the development of other complications or conditions, in particular, pulmonary hypertension, emphysema, an…”
BackgroundInfluentialSelf-citationBUILD-3: A Randomized, Controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis
King, T. E., Brown, K. K., Raghu, G., du Bois, R. M., Lynch, D. A., Martinez, F., Valeyre, D., Leconte, I., Morganti, A., Roux, S., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201011-1874oc · Cited by 718
Self-citationWells, A. U., Desai, S. R., Rubens, M. B., Goh, N. S. L., Cramer, D., Nicholson, A. G., Colby, T. V., du Bois, R. M., & Hansell, D. M. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2111053 · Cited by 686 · cited 1×
“A composite physiologic index has been developed that may account for emphysema in IPF combining FVC, DLCO, and FEV1 into a formula that correlates better with disease extent by CT than any individual pulmonary function test and may be a more accurate predictor of survival (95, 96).”
BackgroundHistopathologic Variability in Usual and Nonspecific Interstitial Pneumonias
FLAHERTY, K. R., TRAVIS, W. D., COLBY, T. V., TOEWS, G. B., KAZEROONI, E. A., GROSS, B. H., JAIN, A., STRAWDERMAN, R. L., FLINT, A., LYNCH, J. P., et al. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.9.2103074 · Cited by 665 · cited 1×
“Patients in the discordant UIP group show survival, clinical, and physiologic features similar to those found in the concordant UIP group, and importantly, the prognosis in both concordant and discordant UIP groups was significantly worse than that of the concordant nonspecific interstitial pneumonia group (114, 115).”
ResultA placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis
Raghu, G., Brown, K. K., Bradford, W. Z., Starko, K., Noble, P. W., Schwartz, D. A., & King, T. E. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030511 · Cited by 652
Self-citationHigh prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis
Raghu, G., Freudenberger, T. D., Yang, S., Curtis, J. R., Spada, C., Hayes, J., Sillery, J. K., Pope, C. E., & Pellegrini, C. A. (2006) · European Respiratory Journal · doi:10.1183/09031936.06.00037005 · Cited by 643
A Controlled Trial of Sildenafil in Advanced Idiopathic Pulmonary Fibrosis
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002110 · Cited by 634
Idiopathic Pulmonary Fibrosis: Relationship between Histopathologic Features and Mortality
KING, T. E., SCHWARZ, M. I., BROWN, K., TOOZE, J. A., COLBY, T. V., WALDRON, J. A., FLINT, A., THURLBECK, W., & CHERNIACK, R. M. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.6.2001056 · Cited by 628 · cited 1×
“Among these features, fibroblastic foci are hypothesized to play a key role in the pathophysiology of IPF, and their profusion, as assessed by both semiquantitative and quantitative methods, has been shown, in some cohorts, to predict survival (9, 116, 117).”
BackgroundSelf-citationThe Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
Martinez, F. J., Safrin, S., Weycker, D., Starko, K. M., Bradford, W. Z., King, T. E., Flaherty, K. R., Schwartz, D. A., Noble, P. W., Raghu, G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00005 · Cited by 622 · cited 3×
“However, a substantial minority of patients experienced acute deterioration leading to death (sudden worsening of less than 4 wk duration) (Figure 3) (3, 4, 26, 29, 43).”
BackgroundSelf-citationMMP1 and MMP7 as Potential Peripheral Blood Biomarkers in Idiopathic Pulmonary Fibrosis
Rosas, I. O., Richards, T. J., Konishi, K., Zhang, Y., Gibson, K., Lokshin, A. E., Lindell, K. O., Cisneros, J., MacDonald, S. D., Pardo, A., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050093 · Cited by 588 · cited 1×
“Another study demonstrated that MMP-7 negatively correlated with FVC and DLCO, but an association with prognosis was not specifically studied (128).”
BackgroundFibrotic Idiopathic Interstitial Pneumonia: The Prognostic Value of Longitudinal Functional Trends
Latsi, P. I., du Bois, R. M., Nicholson, A. G., Colby, T. V., Bisirtzoglou, D., Nikolakopoulou, A., Veeraraghavan, S., Hansell, D. M., & Wells, A. U. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200210-1245oc · Cited by 583 · cited 2×
“Several studies have demonstrated that 6- to 12-month changes in FVC and DLCO are highly predictive of outcome (10, 97, 98) and become more predictive of prognosis over time than most baseline characteristics, including histopathologic diagnosis (11, 96).”
BackgroundValidation, updating and impact of clinical prediction rules: A review
Toll, D. B., Janssen, K. J. M., Vergouwe, Y., & Moons, K. G. M. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2008.04.008 · Cited by 580 · cited 1×
“Clinical prediction models are statistical models that combine clinical findings from history, physical examination, and/or test results to estimate the probability of an outcome, usually a diagnosis or prognosis (133).”
BackgroundIncreased Prevalence of Gastroesophageal Reflux in Patients with Idiopathic Pulmonary Fibrosis
TOBIN, R. W., POPE, C. E., PELLEGRINI, C. A., EMOND, M. J., SILLERY, J., & RAGHU, G. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.158.6.9804105 · Cited by 570
High-Resolution Computed Tomography in Idiopathic Pulmonary Fibrosis: Diagnosis and Prognosis
Lynch, D. A., Godwin, J. D., Safrin, S., Starko, K. M., Hormel, P., Brown, K. K., Raghu, G., King, T. E., Bradford, W. Z., Schwartz, D. A., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200412-1756oc · Cited by 547
Self-citationRadiological versus histological diagnosis in UIP and NSIP: survival implications
Flaherty, K. R. (2003) · Thorax · doi:10.1136/thorax.58.2.143 · Cited by 539 · cited 1×
“The UIP pattern on HRCT (predominately basilar and subpleural honeycombing) has also been shown to portend a worse prognosis in patients with IPF compared with those with atypical HRCT findings, suggesting that the HRCT pattern adds prognostic information to histopathologic diagnosis (94).”
ResultKing, T. E., Albera, C., Bradford, W. Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., Thomeer, M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60551-1 · Cited by 531 · cited 2×
“However, a substantial minority of patients experienced acute deterioration leading to death (sudden worsening of less than 4 wk duration) (Figure 3) (3, 4, 26, 29, 43).”
BackgroundSelf-citationCirculating Fibrocytes Are an Indicator of Poor Prognosis in Idiopathic Pulmonary Fibrosis
Moeller, A., Gilpin, S. E., Ask, K., Cox, G., Cook, D., Gauldie, J., Margetts, P. J., Farkas, L., Dobranowski, J., Boylan, C., et al. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200810-1534oc · Cited by 513 · cited 1×
“Fibrocytes are mesenchymal cell progenitors involved in tissue repair and fibrosis, and circulating levels are elevated in IPF and increase further during acute exacerbations (131).”
BackgroundIncidence, Prevalence, and Clinical Course of Idiopathic Pulmonary Fibrosis
Fernández Pérez, E. R., Daniels, C. E., St. Sauver, J., Hartman, T. E., Bartholmai, B. J., Yi, E. S., Ryu, J. H., & Schroeder, D. R. (2010) · Chest · doi:10.1378/chest.09-1002 · Cited by 509 · cited 4×
“However, a substantial minority of patients experienced acute deterioration leading to death (sudden worsening of less than 4 wk duration) (Figure 3) (3, 4, 26, 29, 43).”
BackgroundInfluentialBUILD-1: A Randomized Placebo-controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis
King, T. E., Behr, J., Brown, K. K., du Bois, R. M., Lancaster, L., de Andrade, J. A., Stähler, G., Leconte, I., Roux, S., & Raghu, G. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200705-732oc · Cited by 500 · cited 1×
“(IFNg) (25), 4Pirfenidone (30), 5Etanercept (26), 6Bosentan (24), 7N-Acetylcysteine (NAC) (28).”
Self-citationNICHOLSON, A. G., COLBY, T. V., DUBOIS, R. M., HANSELL, D. M., & WELLS, A. U. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.162.6.2003049 · Cited by 489 · cited 1×
“UIP is the histopathologic pattern that identifies IPF, and it carries the worst prognosis among the idiopathic interstitial pneumonias (2, 6, 8).”
BackgroundPulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome
Cottin, V., Le Pavec, J., Prévot, G., Mal, H., Humbert, M., Simonneau, G., Cordier, J.-F., & GERM“O”P (2010) · European Respiratory Journal · doi:10.1183/09031936.00038709 · Cited by 478 · cited 1×
“Early and severe pulmonary arterial hypertension develops in these patients and they have a worse survival compared with patients with IPF without emphysema (74, 75).”
BackgroundIdiopathic Pulmonary Fibrosis and Emphysema
Mejía, M., Carrillo, G., Rojas-Serrano, J., Estrada, A., Suárez, T., Alonso, D., Barrientos, E., Gaxiola, M., Navarro, C., & Selman, M. (2009) · Chest · doi:10.1378/chest.08-2306 · Cited by 468 · cited 1×
“Early and severe pulmonary arterial hypertension develops in these patients and they have a worse survival compared with patients with IPF without emphysema (74, 75).”
BackgroundMortality from Pulmonary Fibrosis Increased in the United States from 1992 to 2003
Olson, A. L., Swigris, J. J., Lezotte, D. C., Norris, J. M., Wilson, C. G., & Brown, K. K. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200701-044oc · Cited by 435
Clinical and Pathologic Features of Familial Interstitial Pneumonia
Steele, M. P., Speer, M. C., Loyd, J. E., Brown, K. K., Herron, A., Slifer, S. H., Burch, L. H., Wahidi, M. M., Phillips, J. A., Sporn, T. A., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200408-1104oc · Cited by 432 · cited 1×
“Asymptomatic, early lung fibrosis has been increasingly recognized and reported in family members of affected individuals with familial pulmonary fibrosis, especially in those with a history of smoking (14, 15).”
BackgroundPulmonary Hypertension in Patients With Idiopathic Pulmonary Fibrosis
Nadrous, H. F., Pellikka, P. A., Krowka, M. J., Swanson, K. L., Chaowalit, N., Decker, P. A., & Ryu, J. H. (2005) · Chest · doi:10.1378/chest.128.4.2393 · Cited by 427 · cited 3×
“In general, factors that are associated with shortened survival time include: older age, smoking history, lower body mass index (BMI), more severe physiologic impairment, greater radiologic extent of disease, and the development of other complications or conditions, in particular, pulmonary hypertension, emphysema, an…”
BackgroundResultAscertainment of Individual Risk of Mortality for Patients with Idiopathic Pulmonary Fibrosis
du Bois, R. M., Weycker, D., Albera, C., Bradford, W. Z., Costabel, U., Kartashov, A., Lancaster, L., Noble, P. W., Raghu, G., Sahn, S. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201011-1790oc · Cited by 424 · cited 3×
“5]), percent predicted DLco, 24-week change in DLCO, and 24-week change in health-related quality of life (100).”
BackgroundMethodSelf-citationSerial Changes in Surfactant-associated Proteins in Lung and Serum before and after Onset of ARDS
GREENE, K. E., WRIGHT, J. R., STEINBERG, K. P., RUZINSKI, J. T., CALDWELL, E., WONG, W. B., HULL, W., WHITSETT, J. A., AKINO, T., KUROKI, Y., et al. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.160.6.9901117 · Cited by 417 · cited 1×
“Surfactant proteins A and D (SP-A and SP-D) are secreted by alveolar type II pneumocytes and increase in the blood in association with breakdown of the alveolar epithelium (121).”
BackgroundSix-Minute-Walk Distance Predicts Waiting List Survival in Idiopathic Pulmonary Fibrosis
Lederer, D. J., Arcasoy, S. M., Wilt, J. S., D'Ovidio, F., Sonett, J. R., & Kawut, S. M. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200604-520oc · Cited by 402 · cited 1×
“Both distance walked (105, 106) and desaturation (97, 107) during the 6MWT have been found to predict mortality, and a composite of the product of distance and desaturation in one study predicted mortality better than either measure alone (108).”
BackgroundHamada, K., Nagai, S., Tanaka, S., Handa, T., Shigematsu, M., Nagao, T., Mishima, M., Kitaichi, M., & Izumi, T. (2007) · Chest · doi:10.1378/chest.06-1466 · Cited by 390 · cited 13×
“In fact, a prediction formula using room air saturation, DLCO, and FVC demonstrated modest accuracy and high sensitivity for detecting pulmonary hypertension in IPF, suggesting a role in screening for pulmonary hypertension (66).”
BackgroundInfluentialDANIIL, Z. D., GILCHRIST, F. C., NICHOLSON, A. G., HANSELL, D. M., HARRIS, J., COLBY, T. V., & du BOIS, R. M. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.160.3.9903021 · Cited by 381
Idiopathic Pulmonary Fibrosis: Prognostic Value of Changes in Physiology and Six-Minute-Walk Test
Flaherty, K. R., Andrei, A.-C., Murray, S., Fraley, C., Colby, T. V., Travis, W. D., Lama, V., Kazerooni, E. A., Gross, B. H., Toews, G. B., et al. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200604-488oc · Cited by 380 · cited 2×
“Both distance walked (105, 106) and desaturation (97, 107) during the 6MWT have been found to predict mortality, and a composite of the product of distance and desaturation in one study predicted mortality better than either measure alone (108).”
BackgroundImatinib Treatment for Idiopathic Pulmonary Fibrosis: Randomized Placebo-controlled Trial Results
Daniels, C. E., Lasky, J. A., Limper, A. H., Mieras, K., Gabor, E., & Schroeder, D. R. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200906-0964oc · Cited by 373 · cited 2×
“trials: 1Pirfenidone (27), 2Imatinib (29), 3Interferon g-1b”
BackgroundClinical significance of histological classification of idiopathic interstitial pneumonia
Flaherty, K. R., Toews, G. B., Travis, W. D., Colby, T. V., Kazerooni, E. A., Gross, B. H., Jain, A., Strawderman, R. L., Paine, R., Flint, A., et al. (2002) · European Respiratory Journal · doi:10.1183/09031936.02.00182002 · Cited by 372
Zappala, C. J., Latsi, P. I., Nicholson, A. G., Colby, T. V., Cramer, D., Renzoni, E. A., Hansell, D. M., du Bois, R. M., & Wells, A. U. (2010) · European Respiratory Journal · doi:10.1183/09031936.00155108 · Cited by 372 · cited 2×
“Only changes greater than 15% in DLCO were predictive of mortality risk (99).”
BackgroundTreatment of Idiopathic Pulmonary Fibrosis with Etanercept: An Exploratory, Placebo-controlled Trial
Raghu, G., Brown, K. K., Costabel, U., Cottin, V., du Bois, R. M., Lasky, J. A., Thomeer, M., Utz, J. P., Khandker, R. K., McDermott, L., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200709-1446oc · Cited by 370 · cited 2×
“(IFNg) (25), 4Pirfenidone (30), 5Etanercept (26), 6Bosentan (24), 7N-Acetylcysteine (NAC) (28).”
BackgroundClinical deterioration in patients with idiopathic pulmonary fibrosis: Causes and assessment
Panos, R. J., Mortenson, R. L., Niccoli, S. A., & King, T. E. (1990) · The American Journal of Medicine · doi:10.1016/0002-9343(90)90495-y · Cited by 367
Self-citationComputed Tomography Findings in Pathological Usual Interstitial Pneumonia: Relationship to Survival
Sumikawa, H., Johkoh, T., Colby, T. V., Ichikado, K., Suga, M., Taniguchi, H., Kondoh, Y., Ogura, T., Arakawa, H., Fujimoto, K., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200611-1696oc · Cited by 354 · cited 1×
“However, other studies demonstrate that in patients with histologic UIP, the prognosis of patients with the UIP pattern on HRCT is similar to those with an atypical pattern (89, 92).”
ResultDeterminants of survival in idiopathic pulmonary fibrosis.
Schwartz, D. A., Helmers, R. A., Galvin, J. R., Van Fossen, D. S., Frees, K. L., Dayton, C. S., Burmeister, L. F., & Hunninghake, G. W. (1994) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.149.2.8306044 · Cited by 340 · cited 1×
“IPF is more common in men, but sex differences in survival have been inconsistent (22, 48, 51).”
ResultNagai, S., Kitaichi, M., Itoh, H., Nishimura, K., Izumi, T., & Colby, T. (1998) · European Respiratory Journal · doi:10.1183/09031936.98.12051010 · Cited by 339
Serum CC-Chemokine Ligand 18 Concentration Predicts Outcome in Idiopathic Pulmonary Fibrosis
Prasse, A., Probst, C., Bargagli, E., Zissel, G., Toews, G. B., Flaherty, K. R., Olschewski, M., Rottoli, P., & Müller-Quernheim, J. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200808-1201oc · Cited by 328 · cited 1×
“In serum, CCL-18, a CC chemokine produced by alveolar macrophages, was recently shown to be a strong and independent predictor of mortality (129).”
BackgroundBest, A. C., Meng, J., Lynch, A. M., Bozic, C. M., Miller, D., Grunwald, G. K., & Lynch, D. A. (2008) · Radiology · doi:10.1148/radiol.2463062200 · Cited by 323
Serum surfactant proteins‐A and ‐D as biomarkers in idiopathic pulmonary fibrosis
Greene, K. E., King, T. E., Kuroki, Y., Bucher-Bartelson, B., Hunninghake, G. W., Newman, L. S., Nagae, H., & Mason, R. J. (2002) · European Respiratory Journal · doi:10.1183/09031936.02.00081102 · Cited by 316 · cited 1×
“Levels in BAL fluid and blood were shown to predict survival in patients before current international consensus guidelines for IPF (122, 123).”
BackgroundSelf-citationPhysiology Is a Stronger Predictor of Survival than Pathology in Fibrotic Interstitial Pneumonia
Jegal, Y., Kim, D. S., Shim, T. S., Lim, C.-M., Do Lee, S., Koh, Y., Kim, W. S., Kim, W. D., Lee, J. S., Travis, W. D., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200403-331oc · Cited by 308 · cited 1×
“Several studies have demonstrated that 6- to 12-month changes in FVC and DLCO are highly predictive of outcome (10, 97, 98) and become more predictive of prognosis over time than most baseline characteristics, including histopathologic diagnosis (11, 96).”
BackgroundPrognostic value of circulating KL‐6 in idiopathic pulmonary fibrosis
YOKOYAMA, A., KONDO, K., NAKAJIMA, M., MATSUSHIMA, T., TAKAHASHI, T., NISHIMURA, M., BANDO, M., SUGIYAMA, Y., TOTANI, Y., ISHIZAKI, T., et al. (2006) · Respirology · doi:10.1111/j.1440-1843.2006.00834.x · Cited by 304 · cited 1×
“Krebs von den Lungen-6 (KL-6) is a high molecular weight mucin-like glycoprotein (human MUC1 mucin) that is a sensitive marker for interstitial lung diseases, and patients with IPF with higher KL-6 levels may have reduced survival (120).”
BackgroundBaseline BAL Neutrophilia Predicts Early Mortality in Idiopathic Pulmonary Fibrosis
Kinder, B. W., Brown, K. K., Schwarz, M. I., Ix, J. H., Kervitsky, A., & King, T. E. (2008) · Chest · doi:10.1378/chest.07-1948 · Cited by 302
Self-citationNicholson, A. G., Fulford, L. G., Colby, T. V., du Bois, R. M., Hansell, D. M., & Wells, A. U. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2109039 · Cited by 299 · cited 1×
“Among these features, fibroblastic foci are hypothesized to play a key role in the pathophysiology of IPF, and their profusion, as assessed by both semiquantitative and quantitative methods, has been shown, in some cohorts, to predict survival (9, 116, 117).”
BackgroundTAKAHASHI, H., FUJISHIMA, T., KOBA, H., MURAKAMI, S., KUROKAWA, K., SHIBUYA, Y., SHIRATORI, M., KUROKI, Y., & ABE, S. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.162.3.9910080 · Cited by 291
Health-related quality of life in patients with idiopathic pulmonary fibrosis: a systematic review
Swigris, J. J. (2005) · Thorax · doi:10.1136/thx.2004.035220 · Cited by 275
Six-Minute Walk, Maximal Exercise Tests: Reproducibility in Fibrotic Interstitial Pneumonia
Eaton, T., Young, P., Milne, D., & Wells, A. U. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200405-578oc · Cited by 274 · cited 1×
“In most lung diseases, including IPF, the 6MWT has become the most widely used exercise test, given its ease of administration and reproducibility (103, 104).”
BackgroundAccelerated Variant of Idiopathic Pulmonary Fibrosis: Clinical Behavior and Gene Expression Pattern
Selman, M., Carrillo, G., Estrada, A., Mejia, M., Becerril, C., Cisneros, J., Gaxiola, M., Pérez-Padilla, R., Navarro, C., Richards, T., et al. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000482 · Cited by 270
Self-citationLederer, D. J., Enright, P. L., Kawut, S. M., Hoffman, E. A., Hunninghake, G., van Beek, E. J. R., Austin, J. H. M., Jiang, R., Lovasi, G. S., & Barr, R. G. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200812-1966oc · Cited by 270
Clinical Predictors of a Diagnosis of Idiopathic Pulmonary Fibrosis
Fell, C. D., Martinez, F. J., Liu, L. X., Murray, S., Han, M. K., Kazerooni, E. A., Gross, B. H., Myers, J., Travis, W. D., Colby, T. V., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200906-0959oc · Cited by 243 · cited 3×
“Recently, Fell and colleagues have suggested that age, combined with findings on HRCT, is a useful diagnostic tool that identifies patients with IPF (49).”
BackgroundThe Association between Idiopathic Pulmonary Fibrosis and Vascular Disease: A Population-based Study
Hubbard, R. B., Smith, C., Le Jeune, I., Gribbin, J., & Fogarty, A. W. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200805-725oc · Cited by 238
Nathan, S. D., Shlobin, O. A., Barnett, S. D., Saggar, R., Belperio, J. A., Ross, D. J., Ahmad, S., Saggar, R., Libre, E., Lynch, J. P., et al. (2008) · Respiratory Medicine · doi:10.1016/j.rmed.2008.03.022 · Cited by 238 · cited 1×
“However, its test characteristics are poor, with an accuracy of only 40% when compared with right-sided heart catheterization (64).”
BackgroundPulmonary Function in Idiopathic Pulmonary Fibrosis and Referral for Lung Transplantation
MOGULKOC, N., BRUTSCHE, M. H., BISHOP, P. W., GREAVES, S. M., HORROCKS, A. W., & EGAN, J. J. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.1.2007077 · Cited by 238 · cited 13×
“In fact, a prediction formula using room air saturation, DLCO, and FVC demonstrated modest accuracy and high sensitivity for detecting pulmonary hypertension in IPF, suggesting a role in screening for pulmonary hypertension (66).”
BackgroundInfluentialIdentification of Early Interstitial Lung Disease in Smokers from the COPDGene Study
Washko, G. R., Lynch, D. A., Matsuoka, S., Ross, J. C., Umeoka, S., Diaz, A., Sciurba, F. C., Hunninghake, G. M., San José Estépar, R., Silverman, E. K., et al. (2010) · Academic Radiology · doi:10.1016/j.acra.2009.07.016 · Cited by 232 · cited 1×
“Cigarette smoking, a known a risk factor for some idiopathic interstitial pneumonias, including IPF (16), may cause subclinical parenchymal lung disease detectable by spirometry and computed tomography (CT) imaging, even among a generally healthy cohort (17, 18).”
BackgroundWiggins, J., Strickland, B., & Turner-Warwick, M. (1990) · Respiratory Medicine · doi:10.1016/s0954-6111(08)80070-4 · Cited by 230
Monaghan, H., Wells, A. U., Colby, T. V., du Bois, R. M., Hansell, D. M., & Nicholson, A. G. (2004) · Chest · doi:10.1378/chest.125.2.522 · Cited by 230 · cited 1×
“Patients in the discordant UIP group show survival, clinical, and physiologic features similar to those found in the concordant UIP group, and importantly, the prognosis in both concordant and discordant UIP groups was significantly worse than that of the concordant nonspecific interstitial pneumonia group (114, 115).”
ResultFulmer, J. D., Roberts, W. C., von Gal, E. R., & Crystal, R. G. (1979) · Journal of Clinical Investigation · doi:10.1172/jci109349 · Cited by 229
Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension: Connecting the Dots
Nathan, S. D., Noble, P. W., & Tuder, R. M. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200608-1153cc · Cited by 227
Serial Development of Pulmonary Hypertension in Patients with Idiopathic Pulmonary Fibrosis
Nathan, S. D., Shlobin, O. A., Ahmad, S., Koch, J., Barnett, S. D., Ad, N., Burton, N., & Leslie, K. (2008) · Respiration · doi:10.1159/000114246 · Cited by 227
The six-minute walk test: a guide to assessment for lung transplantation.
Kadikar, A., Maurer, J., & Kesten, S. (1997) · PubMed · Cited by 220
Does Chronic Microaspiration Cause Idiopathic Pulmonary Fibrosis?
Lee, J. S., Collard, H. R., Raghu, G., Sweet, M. P., Hays, S. R., Campos, G. M., Golden, J. A., & King, T. E. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.07.033 · Cited by 209 · cited 1×
“Moreover, although a causal relationship is unclear, it has been hypothesized that gastroesophageal reflux may be a risk factor for microaspiration, and this may be important in the pathogenesis and natural history of IPF (84).”
BackgroundSelf-citationSerum Surfactant Protein-A Is a Strong Predictor of Early Mortality in Idiopathic Pulmonary Fibrosis
Kinder, B. W., Brown, K. K., McCormack, F. X., Ix, J. H., Kervitsky, A., Schwarz, M. I., & King, T. E. (2009) · Chest · doi:10.1378/chest.08-2209 · Cited by 209 · cited 1×
“In serum, SP-A and SP-D levels appear to be independent predictors of mortality (125, 126), and their addition to clinical predictors alone may improve prediction of 1-year mortality (126).”
BackgroundSelf-citationZisman, D. A., Karlamangla, A. S., Ross, D. J., Keane, M. P., Belperio, J. A., Saggar, R., Lynch, J. P., Ardehali, A., & Goldin, J. (2007) · Chest · doi:10.1378/chest.07-0116 · Cited by 209 · cited 1×
“Main pulmonary artery diameter as measured by HRCT is an unreliable predictor of pulmonary hypertension in IPF (65).”
BackgroundPrevalence and impact of coronary artery disease in idiopathic pulmonary fibrosis
Nathan, S. D., Basavaraj, A., Reichner, C., Shlobin, O. A., Ahmad, S., Kiernan, J., Burton, N., & Barnett, S. D. (2010) · Respiratory Medicine · doi:10.1016/j.rmed.2010.02.008 · Cited by 205
MMP expression and abnormal lung permeability are important determinants of outcome in IPF
McKeown, S., Richter, A. G., O'Kane, C., McAuley, D. F., & Thickett, D. R. (2009) · European Respiratory Journal · doi:10.1183/09031936.00060708 · Cited by 200 · cited 1×
“MMP-3, -7, -8, and -9 levels in BAL fluid were elevated in patients who died early in follow-up in one study (127).”
BackgroundIdiopathic Pulmonary Fibrosis: Outcome in Relation to Smoking Status
Antoniou, K. M., Hansell, D. M., Rubens, M. B., Marten, K., Desai, S. R., Siafakas, N. M., Nicholson, A. G., du Bois, R. M., & Wells, A. U. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200612-1759oc · Cited by 191 · cited 1×
“A study specifically investigating the impact of smoking status on IPF also demonstrated this survival advantage in current smokers compared with former smokers on univariate analysis, but after adjustment for disease severity, this effect was no longer significant, indicating a ‘‘healthy smoker effect’’ (55).”
ResultThe timed walk test as a measure of severity and survival in idiopathic pulmonary fibrosis
Hallstrand, T. S., Boitano, L. J., Johnson, W. C., Spada, C. A., Hayes, J. G., & Raghu, G. (2005) · European Respiratory Journal · doi:10.1183/09031936.04.00137203 · Cited by 188 · cited 1×
“Both distance walked (105, 106) and desaturation (97, 107) during the 6MWT have been found to predict mortality, and a composite of the product of distance and desaturation in one study predicted mortality better than either measure alone (108).”
BackgroundBody Mass Index and Mortality in Patients With Idiopathic Pulmonary Fibrosis
Alakhras, M., Decker, P. A., Nadrous, H. F., Collazo-Clavell, M., & Ryu, J. H. (2007) · Chest · doi:10.1378/chest.06-2784 · Cited by 186 · cited 2×
“In general, factors that are associated with shortened survival time include: older age, smoking history, lower body mass index (BMI), more severe physiologic impairment, greater radiologic extent of disease, and the development of other complications or conditions, in particular, pulmonary hypertension, emphysema, an…”
BackgroundThe distance-saturation product predicts mortality in idiopathic pulmonary fibrosis
Lettieri, C. J., Nathan, S. D., Browning, R. F., Barnett, S. D., Ahmad, S., & Shorr, A. F. (2006) · Respiratory Medicine · doi:10.1016/j.rmed.2006.02.004 · Cited by 184 · cited 1×
“Both distance walked (105, 106) and desaturation (97, 107) during the 6MWT have been found to predict mortality, and a composite of the product of distance and desaturation in one study predicted mortality better than either measure alone (108).”
BackgroundBoon, K., Bailey, N. W., Yang, J., Steel, M. P., Groshong, S., Kervitsky, D., Brown, K. K., Schwarz, M. I., & Schwartz, D. A. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005134 · Cited by 183 · cited 1×
“Boon and colleagues also showed that lung molecular signatures at the time of diagnosis may identify patients with stable IPF compared with those with rapidly progressive disease (31).”
ResultEarly Interstitial Lung Disease in Familial Pulmonary Fibrosis
Rosas, I. O., Ren, P., Avila, N. A., Chow, C. K., Franks, T. J., Travis, W. D., McCoy, J. P., May, R. M., Wu, H.-P., Nguyen, D. M., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200702-254oc · Cited by 180 · cited 4×
“Improved understanding is important because the prevalence of subclinical IPF is likely to increase with increasing trends in the use of chest CT imaging for non-ILD diseases, such as diagnosis of pulmonary embolism and coronary artery disease.”
BackgroundInfluentialAssociation of Malignancy With Diseases Causing Interstitial Pulmonary Changes
Bouros, D., Hatzakis, K., Labrakis, H., & Zeibecoglou, K. (2002) · Chest · doi:10.1378/chest.121.4.1278 · Cited by 178 · cited 1×
“8 to 38%) and has a substantial impact on prognosis (86).”
BackgroundWalking distance on 6-MWT is a prognostic factor in idiopathic pulmonary fibrosis
Caminati, A., Bianchi, A., Cassandro, R., Mirenda, M. R., & Harari, S. A. (2008) · Respiratory Medicine · doi:10.1016/j.rmed.2008.07.022 · Cited by 171 · cited 1×
“Both distance walked (105, 106) and desaturation (97, 107) during the 6MWT have been found to predict mortality, and a composite of the product of distance and desaturation in one study predicted mortality better than either measure alone (108).”
BackgroundLung Function Tests in Patients With Idiopathic Pulmonary Fibrosis
Erbes, R., Schaberg, T., & Loddenkemper, R. (1997) · Chest · doi:10.1378/chest.111.1.51 · Cited by 171
Sweet, M. P., Patti, M. G., Leard, L. E., Golden, J. A., Hays, S. R., Hoopes, C. W., & Theodore, P. R. (2007) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2006.09.085 · Cited by 162
The ‘Healthy Smoker’: A Phenomenon of Health Selection?
Becklake, M. R., & Lalloo, U. (1990) · Respiration · doi:10.1159/000195837 · Cited by 158
Swigris, J. J., Wamboldt, F. S., Behr, J., du Bois, R. M., King, T. E., Raghu, G., & Brown, K. K. (2010) · Thorax · doi:10.1136/thx.2009.113498 · Cited by 156
Self-citationShin, K. M., Lee, K. S., Chung, M. P., Han, J., Bae, Y. A., Kim, T. S., & Chung, M. J. (2008) · Radiology · doi:10.1148/radiol.2483071378 · Cited by 146 · cited 13×
“In fact, a prediction formula using room air saturation, DLCO, and FVC demonstrated modest accuracy and high sensitivity for detecting pulmonary hypertension in IPF, suggesting a role in screening for pulmonary hypertension (66).”
BackgroundInfluentialCoexistent emphysema delays the decrease of vital capacity in idiopathic pulmonary fibrosis
Akagi, T., Matsumoto, T., Harada, T., Tanaka, M., Kuraki, T., Fujita, M., & Watanabe, K. (2009) · Respiratory Medicine · doi:10.1016/j.rmed.2009.02.001 · Cited by 143 · cited 2×
“One difficulty with interpreting these measures is confounding by obstructive lung disease, especially emphysema, which causes less of a decline in lung volumes and a greater decline in gas exchange (72).”
BackgroundMannino, D. M., Etzel, R. A., & Parrish, R. G. (1996) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.153.5.8630600 · Cited by 140 · cited 1×
“A study prior to consensus guidelines suggested higher mortality of whites compared with blacks (40), but two more recent studies of patients listed for lung transplantation found reduced survival among both blacks and Hispanics compared with whites that persisted after adjustment for comorbidities and socioeconomic s…”
ResultHanson, D., Winterbauer, R. H., Kirtland, S. H., & Wu, R. (1995) · CHEST Journal · doi:10.1378/chest.108.2.305 · Cited by 137 · cited 1×
“Several studies have demonstrated that 6- to 12-month changes in FVC and DLCO are highly predictive of outcome (10, 97, 98) and become more predictive of prognosis over time than most baseline characteristics, including histopathologic diagnosis (11, 96).”
BackgroundCryptogenic fibrosing alveolitis with preserved lung volumes
Doherty, M. J., Pearson, M. G., O'Grady, E., Pellegrini, V., & Calverley, P. M. A. (1997) · Thorax · doi:10.1136/thx.52.11.998 · Cited by 134
Sex differences in physiological progression of idiopathic pulmonary fibrosis
Han, M. K., Murray, S., Fell, C. D., Flaherty, K. R., Toews, G. B., Myers, J., Colby, T. V., Travis, W. D., Kazerooni, E. A., Gross, B. H., et al. (2008) · European Respiratory Journal · doi:10.1183/09031936.00165207 · Cited by 127 · cited 1×
“97) after adjusting for age, smoking status, and baseline physiologic variables (52).”
BackgroundSurfactant protein A predicts survival in idiopathic pulmonary fibrosis.
McCormack, F. X., King, T. E., Bucher, B. L., Nielsen, L., Mason, R. J., & McCormac, F. X. (1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.152.2.7633738 · Cited by 125
Self-citationSilva, C. I. S., Müller, N. L., Fujimoto, K., Kato, S., Ichikado, K., Taniguchi, H., Kondoh, Y., Johkoh, T., & Churg, A. (2007) · Journal of Thoracic Imaging · doi:10.1097/01.rti.0000213588.52343.13 · Cited by 125
Swigris, J. J., Swick, J., Wamboldt, F. S., Sprunger, D. B., du Bois, R. M., Fischer, A., Cosgrove, G. P., Frankel, S. K., Pérez, E. R. F., Kervitsky, D. J., et al. (2009) · CHEST Journal · doi:10.1378/chest.09-0211 · Cited by 119 · cited 1×
“Also, abnormal heart rate recovery after 1 minute of rest after the 6MWT may be a novel and powerful predictor of mortality (109).”
BackgroundQuantitative Analysis of Fibroblastic Foci in Usual Interstitial Pneumonia
Enomoto, N., Suda, T., Kato, M., Kaida, Y., Nakamura, Y., Imokawa, S., Ida, M., & Chida, K. (2006) · CHEST Journal · doi:10.1378/chest.130.1.22 · Cited by 118 · cited 1×
“Among these features, fibroblastic foci are hypothesized to play a key role in the pathophysiology of IPF, and their profusion, as assessed by both semiquantitative and quantitative methods, has been shown, in some cohorts, to predict survival (9, 116, 117).”
BackgroundPulmonary Function Testing in Interstitial Pulmonary Disease
Keogh, B. A., & Crystal, R. G. (1980) · CHEST Journal · doi:10.1378/chest.78.6.856 · Cited by 114
Song, J. W., Song, J., & Kim, D. S. (2008) · Respiratory Medicine · doi:10.1016/j.rmed.2008.11.012 · Cited by 112 · cited 3×
“Several studies have investigated transthoracic echocardiography as a noninvasive means of detecting pulmonary hypertension and have demonstrated that elevated estimated pulmonary artery systolic pressure is associated with reduced survival using thresholds of 40 to 50 mm Hg (46, 63).”
BackgroundHeterogeneity in Combined Pulmonary Fibrosis and Emphysema
Jankowich, M. D., Polsky, M. B., Klein, M., & Rounds, S. (2007) · Respiration · doi:10.1159/000107048 · Cited by 112
Grubstein, A., Bendayan, D., Schactman, I., Cohen, M., Shitrit, D., & Kramer, M. R. (2005) · Respiratory Medicine · doi:10.1016/j.rmed.2004.12.010 · Cited by 106
Idiopathic Pulmonary Fibrosis: How Often Is It Really Idiopathic?
Patti, M. G., Tedesco, P., Golden, J. A., Hays, S. R., Hoopes, C. W., Meneghetti, A. T., Damani, T., & Way, L. W. (2005) · Journal of Gastrointestinal Surgery · doi:10.1016/j.gassur.2005.06.027 · Cited by 100
Surfactant protein-D predicts survival in patients with idiopathic pulmonary fibrosis.
Barlo, N. P., van Moorsel, C. H. M., Ruven, H. J. T., Zanen, P., van den Bosch, J. M. M., & Grutters, J. C. (2009) · Sarcoidosis vasculitis and diffuse lung diseases · Cited by 99
Mura, M., Zompatori, M., Pacilli, A. M. G., Fasano, L., Schiavina, M., & Fabbri, M. (2006) · Respiratory Care · doi:10.4187/respcare.06510257 · Cited by 96
Swigris, J. J., Kuschner, W. G., Kelsey, J. L., & Gould, M. K. (2005) · CHEST Journal · doi:10.1378/chest.127.1.275 · Cited by 86
Zisman, D. A., Karlamangla, A. S., Kawut, S. M., Shlobin, O. A., Saggar, R., Ross, D. J., Schwarz, M. I., Belperio, J. A., Ardehali, A. A., Lynch, J. P., et al. (2008) · CHEST Journal · doi:10.1378/chest.07-2488 · Cited by 81 · cited 1×
“In fact, a prediction formula using room air saturation, DLCO, and FVC demonstrated modest accuracy and high sensitivity for detecting pulmonary hypertension in IPF, suggesting a role in screening for pulmonary hypertension (66).”
MethodManali, E. D., Stathopoulos, G. T., Kollintza, A., Kalomenidis, I., Milic‐Emili, J., Sotiropoulou, C., Daniil, Z. D., Roussos, C., & Papiris, S. A. (2008) · Respiratory Medicine · doi:10.1016/j.rmed.2007.11.008 · Cited by 78 · cited 14×
“In fact, a prediction formula using room air saturation, DLCO, and FVC demonstrated modest accuracy and high sensitivity for detecting pulmonary hypertension in IPF, suggesting a role in screening for pulmonary hypertension (66).”
BackgroundInfluentialThe Age of Idiopathic Pulmonary Fibrosis
Collard, H. R. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201001-0049ed · Cited by 75 · cited 2×
“Consequently, physicians will need to pay more attention to geriatric comorbidities and increase focus on symptom-based management techniques as a complement to emerging disease-modifying therapies (49, 50).”
BackgroundSelf-citationShinoda, H., Tasaka, S., Fujishima, S., Yamasawa, W., Miyamoto, K., Nakano, Y., Kamata, H., Hasegawa, N., & Ishizaka, A. (2009) · Respiration · doi:10.1159/000207617 · Cited by 73 · cited 1×
“In BAL fluid, elevated CCL-2, -17, and -22 may predict poor outcome (130).”
BackgroundLederer, D. J., Caplan‐Shaw, C., O’Shea, M. K., Wilt, J. S., Basner, R. C., Bartels, M. N., Sonett, J. R., Arcasoy, S. M., & Kawut, S. M. (2006) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2005.01205.x · Cited by 73 · cited 1×
“A study prior to consensus guidelines suggested higher mortality of whites compared with blacks (40), but two more recent studies of patients listed for lung transplantation found reduced survival among both blacks and Hispanics compared with whites that persisted after adjustment for comorbidities and socioeconomic s…”
ResultTakeda, A., Enomoto, T., Sanuki, N., Nakajima, T., Takeda, T., Sayama, K., & Kunieda, E. (2008) · Radiation Medicine · doi:10.1007/s11604-008-0261-8 · Cited by 70
PARK, C. S., CHUNG, S. W., KI, S. Y., LIM, G.-I., UH, S.-T., KIM, Y. H., CHOI, D. I., PARK, J. S., LEE, D. W., & KITAICHI, M. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.162.3.9906007 · Cited by 70
Racial and Ethnic Disparities in Idiopathic Pulmonary Fibrosis: A UNOS/OPTN Database Analysis
Lederer, D. J., Arcasoy, S. M., Barr, R. G., Wilt, J. S., Bagiella, E., D'Ovidio, F., Sonett, J. R., & Kawut, S. M. (2006) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2006.01480.x · Cited by 70 · cited 1×
“A study prior to consensus guidelines suggested higher mortality of whites compared with blacks (40), but two more recent studies of patients listed for lung transplantation found reduced survival among both blacks and Hispanics compared with whites that persisted after adjustment for comorbidities and socioeconomic s…”
ResultPulmonary Emphysema followed by Pulmonary Fibrosis of Undetermined Cause
Hiwatari, N., Shimura, S., & Takishima, T. (2009) · Respiration · doi:10.1159/000196235 · Cited by 67
Iwasawa, T., Asakura, A., Sakai, F., Kanauchi, T., Gotoh, T., Ogura, T., Yazawa, T., Nishimura, J., & Inoue, T. (2009) · Journal of Thoracic Imaging · doi:10.1097/rti.0b013e3181a6527d · Cited by 67 · cited 1×
“Interestingly, quantification of fibrosis may be automated by a computer system and predicts survival (93).”
MethodSerum Albumin Concentration and Waiting List Mortality in Idiopathic Interstitial Pneumonia
Zisman, D. A., Kawut, S. M., Lederer, D. J., Belperio, J. A., Lynch, J. P., Schwarz, M. I., Tayek, J. A., Reuben, D. B., & Karlamangla, A. S. (2009) · Chest · doi:10.1378/chest.08-0754 · Cited by 62 · cited 1×
“Albumin levels negatively correlate with prognosis in many diseases and predict survival in patients with idiopathic interstitial pneumonias awaiting transplantation (119).”
BackgroundHospital-based historical cohort study of 234 histologically proven Japanese patients with IPF.
Nagai, S., Kitaichi, M., Hamada, K., Nagao, T., Hoshino, Y., Miki, H., & Izumi, T. (1999) · PubMed · Cited by 62
Chida, M., Ono, S., Hoshikawa, Y., & Kondo, T. (2008) · European Journal of Cardio-Thoracic Surgery · doi:10.1016/j.ejcts.2008.07.028 · Cited by 56
Olson, A. L., Swigris, J. J., Raghu, G., & Brown, K. K. (2008) · CHEST Journal · doi:10.1378/chest.08-0703 · Cited by 49 · cited 1×
“Death rates increase with increasing age, are consistently higher in men than women, and experience seasonal variation, with the highest death rates occurring in the winter, even when infections are excluded (35).”
BackgroundAcute exacerbation of idiopathic pulmonary fibrosis: Role of Chlamydophila pneumoniae infection
TOMIOKA, H., SAKURAI, T., HASHIMOTO, K., & IWASAKI, H. (2007) · Respirology · doi:10.1111/j.1440-1843.2007.01119.x · Cited by 37
Stephan, S., Pereira, C. A. D. C., Coletta, E. M., Ferreira, R. G., Arakaki, J. S. O., & Nery, L. E. (2007) · PubMed · Cited by 36
Collard, H. R., Cool, C. D., Leslie, K. O., Curran‐Everett, D., Groshong, S. D., & Brown, K. K. (2007) · Histopathology · doi:10.1111/j.1365-2559.2006.02554.x · Cited by 30 · cited 2×
“However, neither of these features was found to be predictive of survival (118).”
BackgroundSelf-citationAraya, J., Kawabata, Y., Park, J., Uchiyama, T., Ogata, H., & Sugita, Y. (2008) · Respirology · doi:10.1111/j.1440-1843.2008.01277.x · Cited by 28
Shitrit, D., Rusanov, V., Peled, N., Amital, A., Fuks, L., & Kramer, M. R. (2009) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2008.12.019 · Cited by 26
Battista, G., Zompatori, M., Fasano, L., Pacilli, A. M. G., & Basile, B. (2003) · PubMed · Cited by 24
Fibrose pulmonar idiopática simultânea a enfisema em pacientes tabagistas
Silva, D. R., Gazzana, M. B., Barreto, S. S. M., & Knorst, M. M. (2008) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37132008001000005 · Cited by 23
Millar, A., & Denison, D. M. (1990) · Thorax · doi:10.1136/thx.45.8.602 · Cited by 23
The Impact of Pulmonary Arterial Hypertension on Idiopathic Pulmonary Fibrosis
Fell, C. D., & Martínez, F. J. (2007) · CHEST Journal · doi:10.1378/chest.07-0057 · Cited by 17
[Normal lung volumes in patients with idiopathic pulmonary fibrosis and emphysema].
Casas, J. P., Abbona, H., Robles, A., & López, A. M. (2008) · PubMed · Cited by 8
du Bois, R. M., Albera, C., Costabel, U., Bradford, W. Z., Kartashov, A. I., Noble, P. W., Szwarcberg, J., Thomeer, M., Valeyre, D., Weycker, D. A., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a1103 · Cited by 8 · cited 1×
“e, the smallest change in distance that patients can perceive as different from the previous test and that would mandate, in the absence of troublesome side effects and excessive costs, a change in management) (110, 111).”
BackgroundSelf-citationFamilial Pulmonary Fibrosis: Natural History Of Preclinical Disease
El‐Chemaly, S., Ziegler, S. G., Wilson, K. A., Gahl, W. A., Moss, J., & Gochuico, B. R. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a2980 · Cited by 5 · cited 1×
“Progression of asymptomatic to symptomatic IPF may occur over years to decades (13).”
BackgroundAscertainment Of Individual Risk Of Mortality For Patients With Idiopathic Pulmonary Fibrosis (IPF)
du Bois, R. M., Albera, C., Bradford, W. Z., Costabel, U., Kartashov, A. I., Noble, P. W., Raghu, G., Szwarcberg, J., Thomeer, M., Valeyre, D., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a2499 · Cited by 4
Self-citationHarrell, F., Jr. (1996) · doi:10.1002/(sici)1097-0258(19960229)15:4<361::aid-sim168>3.0.co;2-4
Research works printed but not linked: 137
- 2000, Am J Respir Crit Care Med, 646
- 2002, Am J Respir Crit Care Med, 277
- 2010, Chest, 129
- 2005, Ann Intern Med, 963
- 2005, Chest, 275
- 1998, Am J Respir Crit Care Med, 199
- 1999, Sarcoidosis Vasc Diffuse Lung Dis, 209
- 2000, Am J Respir Crit Care Med, 2213
- 2001, Am J Respir Crit Care Med, 1025
- 2003, Am J Respir Crit Care Med, 538
- 2005, Am J Respir Crit Care Med, 639
- 1998, Eur Respir J, 131s
- 2010, Am J Respir Crit Care Med, A2980
- 2005, Am J Respir Crit Care Med, 1146
- 2007, Am J Respir Crit Care Med, 698
- 1997, Am J Respir Crit Care Med, 242
- 2009, Am J Respir Crit Care Med, 407
- 2010, Acad Radiol, 48
- 2008, Eur J Cardiothorac Surg, 878
- 2008, Respirology, 408
- 2008, Radiat Med, 504
- 2001, Am J Respir Crit Care Med, 1171
- 2007, PLoS ONE, e482
- 2008, Am J Respir Crit Care Med, 75
- 2004, N Engl J Med, 125
- 2008, Am J Respir Crit Care Med, 948
- 2005, Am J Respir Crit Care Med, 1040
- 2001, Am J Respir Crit Care Med, A708
- 2010, Am J Respir Crit Care Med, 604
- 2010, Eur Respir J, 821
- 2009, PLoS ONE, e5134
- 2007, Am J Respir Crit Care Med, 636
- 2007, Respirology, 700
- 2007, J Thorac Imaging, 221
- 2009, Chest, 16
- 2002, Eur Respir J, 275
- 1998, Eur Respir J, 1010
- 1999, Am J Respir Crit Care Med, 899
- 2000, Am J Respir Crit Care Med, 1162
- 1996, Am J Respir Crit Care Med, 1548
- 1990, Am J Med, 396
- 2007, Am J Respir Crit Care Med, 277
- 2009, Lancet, 222
- 2008, Am J Respir Crit Care Med, 1257
- 2007, Chest, 1448
- 2005, Chest, 2393
- 2006, Am J Respir Crit Care Med, 810
- 1997, Chest, 51
- 2010, Am J Respir Crit Care Med, 832
- 2010, Am J Respir Crit Care Med, 771
- 1994, Am J Respir Crit Care Med, 450
- 2008, Eur Respir J, 1183
- 2006, Am J Transplant, 398
- 2006, Am J Transplant, 2436
- 2008, Am J Respir Crit Care Med, 190
- 1990, Respiration, 137
- 2008, Respir Med, 586
- 2006, Chest, 746
- 2007, Chest, 650
- 2007, Chest, 641
- 2007, Am J Respir Crit Care Med, 875
- 2008, Respiration, 288
- 2009, Respir Med, 180
- 2008, Respir Med, 1305
- 2007, Chest, 773
- 2008, Chest, 640
- 2005, Respir Med, 948
- 2006, Respir Care, 257
- 2008, Respiration, 411
- 2008, Medicina (B Aires), 282
- 2008, J Bras Pneumol, 779
- 2009, Respir Med, 1209
- 2005, Eur Respir J, 586
- 2009, Chest, 10
- 2010, Eur Respir J, 105
- 1990, Thorax, 602
- 1990, Respir Med, 365
- 1993, Respiration, 354
- 1997, Thorax, 998
- 1998, Am J Respir Crit Care Med, 1804
- 2005, J Gastrointest Surg, 1053
- 2006, Eur Respir J, 136
- 2007, J Thorac Cardiovasc Surg, 1078
- 2010, Am J Med, 304
- 2010, Respir Med, 1035
- 2002, Chest, 1278
- 2001, Am J Respir Crit Care Med, 103
- 2003, Radiol Med (Torino), 2
- 2005, Am J Respir Crit Care Med, 488
- 2008, Radiology, 328
- 2008, Radiology, 935
- 2008, Am J Respir Crit Care Med, 433
- 2009, J Thorac Imaging, 216
- 2003, Thorax, 143
- 2003, Am J Respir Crit Care Med, 962
- 2003, Am J Respir Crit Care Med, 531
- 2006, Am J Respir Crit Care Med, 803
- 1995, Chest, 305
- 2010, Eur Respir J, 830
- 2010, Am J Respir Crit Care Med, A2499
- 1979, J Clin Invest, 665
- 1980, Chest, 856
- 2005, Am J Respir Crit Care Med, 1150
- 1997, J Heart Lung Transplant, 313
- 2006, Am J Respir Crit Care Med, 659
- 2009, Respir Med, 117
- 2005, Eur Respir J, 96
- 2006, Respir Med, 1734
- 2009, Chest, 841
- 2010, Am J Respir Crit Care Med, A1103
- 2010, Thorax, 173
- 2009, J Heart Lung Transplant, 328
- 2007, Sarcoidosis Vasc Diffuse Lung Dis, 70
- 2001, Am J Respir Crit Care Med, 1722
- 2004, Chest, 522
- 2002, Am J Respir Crit Care Med, 173
- 2006, Chest, 22
- 2007, Histopathology, 258
- 2009, Chest, 929
- 2006, Respirology, 164
- 1999, Am J Respir Crit Care Med, 1843
- 2002, Eur Respir J, 439
- 1995, Am J Respir Crit Care Med, 751
- 2000, Am J Respir Crit Care Med, 1109
- 2009, Sarcoidosis Vasc Diffuse Lung Dis, 155
- 2009, Chest, 1557
- 2009, Eur Respir J, 77
- 2008, PLoS Med, e93
- 2009, Am J Respir Crit Care Med, 717
- 2009, Respiration, 285
- 2009, Am J Respir Crit Care Med, 588
- 2008, Chest, 226
- 2008, J Clin Epidemiol, 1085
- 1996, Stat Med, 361
- 1997, JAMA, 488
- 2005, Thorax, 588
- 2010, N Engl J Med, 620
Cited by
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Self-citationRicheldi, L., Collard, H. R., & Jones, M. G. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30866-8 · Cited by 2,020
Self-citationA Multidimensional Index and Staging System for Idiopathic Pulmonary Fibrosis
Ley, B., Ryerson, C. J., Vittinghoff, E., Ryu, J. H., Tomassetti, S., Lee, J. S., Poletti, V., Buccioli, M., Elicker, B. M., Jones, K. D., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-10-201205150-00004 · Cited by 1,308
Self-citationSenolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study
Justice, J. N., Nambiar, A. M., Tchkonia, T., LeBrasseur, N. K., Pascual, R., Hashmi, S. K., Prata, L., Masternak, M. M., Kritchevsky, S. B., Musi, N., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2018.12.052 · Cited by 1,261
Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Metadata
- Authors
- Ley, B., Collard, H. R., & King, T. E.
- Affiliations
- University of California, San Francisco (US)
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-02
- Volume
- 183
- Issue
- 4
- Pages
- 431-440
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2117488044
- Semantic Scholar
- 16b5b19430180723d6ab4df976d3191be5f25bc7
- Cited by
- 1,765
- References
- 142
- Citations by year
- 2026: 75 · 2025: 111 · 2024: 167 · 2023: 153 · 2022: 160 · 2021: 160 · 2020: 158 · 2019: 161 · 2018: 142 · 2017: 118 · 2016: 82 · 2015: 85 · 2014: 73 · 2013: 66 · 2012: 34
- FWCI
- 6.41
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Respiratory and Critical Care Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- idiopathic pulmonary fibrosis, survival prediction, mortality risk factors, clinical course, interstitial lung disease, respiratory failure, clinical prediction model, prognosis
- MeSH terms
- Cause of Death, Humans, Risk Factors, Survival Analysis, Disease Progression, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.